| Suboptimal Antituberculosis drug concentrations and outcomes in small and HIV‐Coinfected children in India: recommendations for dose modifications B Guiastrennec, G Ramachandran, MO Karlsson, AKH Kumar, ... Clinical Pharmacology & Therapeutics 104 (4), 733-741, 2018 | 40 | 2018 |
| In Vitro and In Vivo Modeling of Hydroxypropyl Methylcellulose (HPMC) Matrix Tablet Erosion Under Fasting and Postprandial Status B Guiastrennec, E Söderlind, S Richardson, A Peric, M Bergstrand Pharmaceutical research 34, 847-859, 2017 | 20 | 2017 |
| Mechanism‐based modeling of gastric emptying rate and gallbladder emptying in response to caloric intake B Guiastrennec, DP Sonne, M Hansen, JI Bagger, A Lund, JF Rehfeld, ... CPT: pharmacometrics & systems pharmacology 5 (12), 692-700, 2016 | 20 | 2016 |
| Model‐based prediction of plasma concentration and enterohepatic circulation of total bile acids in humans B Guiastrennec, DP Sonne, M Bergstrand, T Vilsbøll, FK Knop, ... CPT: pharmacometrics & systems pharmacology 7 (9), 603-612, 2018 | 17 | 2018 |
| AMGET, an R‐based postprocessing tool for ADAPT 5 B Guiastrennec, L Wollenberg, A Forrest, S Ait‐Oudhia CPT: Pharmacometrics & Systems Pharmacology 2 (7), 1-10, 2013 | 10 | 2013 |
| Using a semi‐mechanistic model to identify the main sources of variability of metformin pharmacokinetics TB Stage, G Wellhagen, MMH Christensen, B Guiastrennec, K Brøsen, ... Basic & clinical pharmacology & toxicology 124 (1), 105-114, 2019 | 7 | 2019 |
| GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes GI Uenishi, M Repic, JY Yam, A Landuyt, P Saikumar-Lakshmi, T Guo, ... JCI insight 9 (6), 2024 | 4 | 2024 |
| Population pharmacokinetics, exposure-response, and probability of target attainment analyses for tedizolid in adolescent patients with acute bacterial skin and skin structure … D Li, PE Sabato, B Guiastrennec, A Ouerdani, HP Feng, V Duval, ... Antimicrobial Agents and Chemotherapy 65 (12), 10.1128/aac. 00895-21, 2021 | 3 | 2021 |
| Quantitative Model Diagrams (QMD): A New Perspective in Model Evaluation B Guiastrennec, RJ Keizer, MO Karlsson Journal of Pharmacokinetics and Pharmacodynamics 42 (S1), S53-S53, 2015 | 1 | 2015 |
| POPULATION PHARMACOKINETI (POPPK) C, EXPOSURE-RESPONSE AND PROBABILITY OF TARGET ATTAINMENT ANALYSES FOR TEDIZOLID IN ADOLESCENT PATIENTS WITH COMPLICATED SKIN AND SOFT TISSUE … D Li, P Sabato, H Feng, B Guiastrennec, V Duval, P Sears, M Chou, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S95-S95, 2020 | | 2020 |
| Mechanism-based modeling of biological processes involved in oral absorption B Guiastrennec Acta Universitatis Upsaliensis, 2018 | | 2018 |
| METFORMIN RATE OF ABSORPTION AND CLEARANCE IS AFFECTED BY GENETIC VARIANTS IN A POPULATION PHARMACOKINETIC MODEL. TB Stage, K Brosen, MM Christensen, B Guiastrennec, MC Kjellsson CLINICAL PHARMACOLOGY & THERAPEUTICS 99, S84-S84, 2016 | | 2016 |
| Development of a pharmacokinetic population model for atazanavir on a drug user population B Guiastrennec, A Forrest, Q Ma, G Morse PHARMACOTHERAPY 32 (5), E115-E115, 2012 | | 2012 |
| 2024 Rome, Italy B Guiastrennec, DP Sonne, O Alskär, M Hansen, JI Bagger, A Lund, ... | | |
| Population Approach Group Europe Population Approach Group Europe B Guiastrennec | | |
| Development of a population pharmacokinetic model for Atazanavir in drug using subjects B Guiastrennec, A Forrest, Q Ma, GD Morse | | |
